ALDX - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics Inc. (ALDX) | Benzinga

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 29, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX) securities between March 17, 2022 and June 20, 2023, inclusive (the "Class Period").

If you suffered a loss on your Aldeyra investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Aldeyra-Therapeutics-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On June 21, 2023, Aldeyra disclosed that it had received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") regarding the Company's New Drug Application ("NDA") for its vitreoretinal lymphoma treatment, ADX-2191. ...

ALDX)>Full story available on Benzinga.com